Targets of RUNX1 in the AML-specific GRN include, for example, the apoptosis regulator BCL2 which is upregulated in CEBPAN/C AML blasts, and which could be inhibited by Venetoclax [48]. The gene discussed is GRN; the disease is acute myeloid leukemia.